CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,164 enrolled
Drug / intervention
TRADIANCE® Combination Tablets AP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03761797
NCT03761797N/ACompleted
CompareCT.gov

Post Marketing Surveillance in Japan on Long Term Drug Use of TRADIANCE® Combination Tablets AP and BP in Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim·observational·Posted Dec 3, 2018·Updated Jan 23, 2023

In Brief

An observational study evaluating TRADIANCE® Combination Tablets AP and TRADIANCE® Combination Tablets BP for Diabetes Mellitus, Type 2. Completed, enrolled 1,164 participants across 1 site.

Detailed Summary

Study objectives is to investigate the safety of long-term daily use of TRADIANCE® Combination Tablets AP and BP in Japanese patients with Type 2 Diabetes mellitus (T2DM) used in routine care.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsEli Lilly and Company

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedDec 3, 2018
Enrollment StartJan 15, 2019
Primary CompletionMar 10, 2021
Study CompletionApr 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.6 years ago

Interventions

TRADIANCE® Combination Tablets APdrug

Fixed dose combination

TRADIANCE® Combination Tablets BPdrug

Fixed dose combination